ZYNLONTA is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Adc Therapeutics America, Inc.. The primary component is Loncastuximab Tesirine.
Product ID | 79952-110_12e3f23c-22e0-43bb-ad49-76adc0fefc0f |
NDC | 79952-110 |
Product Type | Human Prescription Drug |
Proprietary Name | ZYNLONTA |
Generic Name | Loncastuximab Tesirine |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2021-04-30 |
Marketing Category | BLA / |
Application Number | BLA761196 |
Labeler Name | ADC Therapeutics America, Inc. |
Substance Name | LONCASTUXIMAB TESIRINE |
Active Ingredient Strength | 10 mg/2mL |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2021-04-30 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
![]() ZYNLONTA 97571349 not registered Live/Pending |
ADC Therapeutics SA 2022-08-30 |
![]() ZYNLONTA 97571344 not registered Live/Pending |
ADC Therapeutics SA 2022-08-30 |
![]() ZYNLONTA 88506358 not registered Live/Pending |
ADC Therapeutics SA 2019-07-09 |